Cima Labs, U.S.-based maker of Fentora (fentanyl), a painkiller for cancer patients, will get to keep its India patent for the oral version of the drug, at least for now.
The opening of Hospira's new plant in India that it is counting on to lower its manufacturing costs will be delayed again after it racked up another set of observations during a reinspection by the FDA last month. Unless quickly resolved, it will be an issue that Pfizer will inherit given its $15 billion buyout of Hospira announced last month.
Gilead Sciences has been busy in India and Japan signing licensing agreements for at least four of its drugs.
Japan's Takeda Pharmaceutical has looked at Indian companies in the vaccine space as it moves to tighten focus on that aspect of its business ahead of a Phase III trial for a dengue candidate and more broadly emerging markets as seen by a recent M&A deal in Turkey.
India's Central Drugs Standard Control Organization has recommended new guidelines for Phase III trial drug trial waivers.
Indian diagnostics company Thyrocare, which touts itself as "the world's largest thyroid testing laboratory," is planning an IPO on the Indian stock market by the end of June with hopes of raising $85 to $100 million.
Two Indian vaccinemakers are ramping up production of their swine flu vaccines, to replace stocks that were destroyed recently after they expired.
In advance of this year's version of the U.S. list of problem countries in terms of intellectual property protection for patented drugs and other products, the pharma industry made what could be considered a last-ditch effort to limit the use of compulsory licenses.
India's Central Drugs Standard Control Organisation has named and shamed several companies for submitting falsified data on fixed-dose combination and new drug applications.
India's National Pharmaceutical Pricing Authority ordered international makers of cardiac stents to meet with the agency Feb. 25 after several companies failed to submit data about the price of their products.